We are live on ! Find out more
SPRO icon

Spero Therapeutics
SPRO

100 hedge funds and large institutions have $180M invested in Spero Therapeutics in 2022 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 15 increasing their positions, 23 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,360% more call options, than puts

Call options by funds: $219K | Put options by funds: $15K

213% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 8

19% more funds holding

Funds holding: 84 → 100 (+16)

1.4% more ownership

Funds ownership: 61.24% → 62.63% (+1.4%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

35% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 23

43% less capital invested

Capital invested by funds: $316M → $180M (-$137M)

Holders
100
Holders Change
+16
Holders Change %
+19.05%
% of All Funds
1.58%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
25
Increased
15
Reduced
23
Closed
8
Calls
$219K
Puts
$15K
Net Calls
+$204K
Net Calls Change
-$181K

Top Buyers

Rank Fund Capital Flow
1
ACM
Aquilo Capital Management
California
+$3.25M
2
Ameriprise
Ameriprise
Minnesota
+$2.29M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.12M
4
Two Sigma Investments
Two Sigma Investments
New York
+$808K
5
KCM
Knoll Capital Management
Florida
+$717K

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$3.55M
2
GIM
Granahan Investment Management
Massachusetts
-$2.72M
3
Rafferty Asset Management
Rafferty Asset Management
New York
-$560K
4
WJWM
Williams Jones Wealth Management
New York
-$502K
5
IA
IndexIQ Advisors
New York
-$459K
Name Holding Trade Value Shares
Change 		Change in
Stake
BNP Paribas Financial Markets
76
BNP Paribas Financial Markets
France
$21.8K -$66.5K -6,489 -72%
BG
77
Bollard Group
Massachusetts
$19K – – –
Zurich Cantonal Bank
78
Zurich Cantonal Bank
Switzerland
$17K -$13.1K -1,276 -40%
BCV
79
Banque Cantonale Vaudoise
Switzerland
$17K – – –
AIP
80
Ameritas Investment Partners
Nebraska
$15K – – –
Citigroup
81
Citigroup
New York
$14K -$321K -31,323 -95%
PFGIA
82
Patriot Financial Group Insurance Agency
Massachusetts
$10K -$30.2K -2,950 -71%
US Bancorp
83
US Bancorp
Minnesota
$10K – – –
CFB
84
Cullen/Frost Bankers
Texas
$9K – – –
UBS Group
85
UBS Group
Switzerland
$7K -$331K -32,327 -98%
ACA
86
Atlas Capital Advisors
Wyoming
$6.33K – – –
CAPTRUST Financial Advisors
87
CAPTRUST Financial Advisors
North Carolina
$4K – – –
TWC
88
TD Waterhouse Canada
Ontario, Canada
$3.54K – – –
SFG
89
Steward Financial Group
Texas
$3K – – –
T
90
TCWP
Ohio
$3K +$4.35K +425 New
PP
91
PFS Partners
New Jersey
$2.17K – – –
BHWM
92
Beaird Harris Wealth Management
Texas
$2K – – –
HWA
93
Heritage Wealth Advisors
Virginia
$2K – – –
LWANC
94
Laurel Wealth Advisors (North Carolina)
North Carolina
$2K – – –
APC
95
Aspire Private Capital
North Carolina
$1K – – –
Daiwa Securities Group
96
Daiwa Securities Group
Japan
$1K – – –
TFA
97
Toth Financial Advisory
Virginia
$1K – – –
Fidelity Investments
98
Fidelity Investments
Massachusetts
$1K +$1.05K +103 New
QCG
99
Quadrant Capital Group
Ohio
$1K +$1.09K +106 New
Rafferty Asset Management
100
Rafferty Asset Management
New York
– -$560K -34,958 Closed
1 2 3
4
5

SPRO Hedge Fund Activity: Q1 2022 in Review

100 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q1 2022, worth a combined $180M — down 43% from $316M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new SPRO positions and 8 closed out — a net gain of 17 holders — while 15 added to existing stakes and 23 trimmed.

The largest buyer was Aquilo Capital Management, adding an estimated $3.25M. The largest seller was State Street, cutting an estimated $3.55M.

  • 100 institutional investors held Spero Therapeutics (SPRO) as of Q1 2022, up from 84 in Q4 2021.
  • Funds reported $180M of Spero Therapeutics stock for Q1 2022, down 43% quarter-over-quarter.
  • 25 funds opened new Spero Therapeutics positions in Q1 2022 and 8 closed out, a net change of +17 holders.
  • The largest Spero Therapeutics buyer in Q1 2022 was Aquilo Capital Management, an estimated $3.25M added.
  • The largest Spero Therapeutics seller in Q1 2022 was State Street, an estimated $3.55M sold.

Based on aggregated 13F filings for Q1 2022.